

**DOCTOR'S ORDER SHEET -**PHARMACY – ACTEMRA (tocilizumab) Place patient identification sticker here

Allergies:	NKA Height Weight _	kg
QD, QC	****UNAPPROVED ABBREVIATIONS**** D, MgSO₄, MSO₄, MS, IU, U or -u, ug, Use of a Trailing Zero (X.0mg), Lack of a Leading Zero(	
DATE TIM	E ORDERS	NURSE SIGNATURE
	Assign to Outpatient status	
	PREMEDICATIONS:	
	0.9% sodium chloride (NS) IV at KVO	1
	No pre-medications necessary	
	methylprednisolone sodium succinate injectionmg IV x 1 dose 30 mins prior to infusion	
	diphenhydraminemg IV x1 dose 30 mins prior to infusion	
	diphenhydraminemg PO x 1 dose 30 mins prior to infusion	
	acetaminophen 650mg PO x 1 dose 30 mins prior to infusion	
	MEDICATION:	
	Actemra (tocilizumab) in 0.9% NS 100ml IV infusion	
	Dose: 4mg/kg = Total Dosemg	
	Bmg/kg = Total Dosemg	
	Route: Intravenous	
	Frequency: Once every 4 weeks	
	Infusion Duration: 60 minutes	
	If infusion-related reaction:	<u>_</u>
	1.) STOP infusion immediately;	
	<ul> <li>2.) Increase 0.9% sodium chloride (NS) infusion to wide open rate;</li> <li>3.) Administer PRN medications per infusion reaction medication ordered;</li> </ul>	
	4.) Call Max Cart;	
	5.) Notify MD	
	INFUSION REACTION MEDICATIONS:	
	albuterol inhalation nebulizer solution 2.5mg/0.5ml (concentrated solution)	_
	(Note: dilute with 2.5ml of NS for an albuterol 2.5mg/3ml dose)	
	Dose: 2.5mg via nebulizer as needed for shortness of breath/wheezing	-
	diphenhydrAMINE injectable	
	Dose: 25mg IV x 1 dose for uticaria, pruitis, shortness of breath. May repeat in 15 minutes if	-
	symptoms not resolved	
	EPINEPHrine 1mg/ml (1:1000) injectable	
	Dose: 0.3mg IM x1 dose as needed for anaphylaxis	
	methylPREDNISolone sodium succinate 125mg injection	
	Dose: 125mg IV x1 dose as needed for hypersensitivity	
	NURSING ORDERS:	
	<ul> <li>Weight should be recorded at every visit. Notify physician if weight changed 10% or greater from baseline</li> </ul>	]
	Ensure patient has had TB test or QuantiFERON-TB assay for latent TB prior to start of treatment	
	<ul> <li>Continue with infusion only if patient meets the following criteria:</li> <li>ANC ≥ 2,000 (first dose) or ≥ 1,000 (subsequent doses</li> </ul>	
	<ul> <li>Platelets ≥ 100,000</li> <li>AST/ALT &lt; 1.5 x ULN</li> </ul>	
	• Verify lipid panel drawn prior to initial therapy, at 4 to 8 weeks after initial treatment and every 6 months during treatment. If lipid panel not drawn prior to treatment, instruct patient to have labs	
	<ul> <li>drawn and notify provider, but proceed with infusion.</li> <li>Do not administer tocilizumab and notify provider if patient has a temperature &gt;100°F, complains</li> </ul>	
	<ul> <li>of symptoms of acute viral or bacterial illness, or if patient is taking antibiotics for current infection</li> <li>Monitor patient for signs/symptoms of hypersensitivity during infusion and for 30 mins post-</li> </ul>	
	infusion     Discontinue IV line when therapy complete and patient stabilized	

USE BALL POINT PEN FAX TO PHARMACY **REFERENCES:** Actemra Prescribing Information

Qualified Medical Provider signature

Date

Time

